Lebanese American University Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Beirut Lebanon (1924)

Organization Overview

First Clinical Trial
2011
NCT02594787
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Lebanese American University | Lebanese American University/ LAU Medical Center | Lebanese American University Medical Center

Active Ingredients

Drugs in Phase 4 Trials (2)

dexmedetomidine (precedex) (4 trials)

enoxaparin (lovenox) (1 trial)

Drugs in Phase 3 Trials (2)

ketamine (ketalar) (1 trial)

nigella sativa (1 trial)

Drugs in Phase 2 Trials (1)

menaquinone (vitamin k2) (1 trial)

Drugs in Phase 1 Trials (1)

atorvastatin (lipitor) (1 trial)

Drugs in Other Trials (4)

fentanyl (Innovar) (1 trial)

lidocaine (xylocaine) (2 trials)

phosphorus (1 trial)

remifentanil (ultiva) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Gastroesophageal Reflux (Phase 3)

Pain, Postoperative (Phase 4)

Renal Insufficiency (Phase 4)

Thromboembolism (Phase 4)

Venous Thromboembolism (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 10